WallStreetZenWallStreetZen

NASDAQ: PIRS
Pieris Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PIRS past revenue growth

How has PIRS's revenue growth performed historically?
Company
65.28%
Industry
142.27%
Market
17.7%
PIRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PIRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PIRS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PIRS earnings and revenue history

Current Revenue
$42.8M
Current Earnings
-$24.5M
Current Profit Margin
-57.3%

PIRS Return on Equity

Current Company
-86.7%
Current Industry
-63.5%
Current Market
188%
PIRS's Return on Equity (-86.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PIRS announces earnings.

PIRS Return on Assets

Current Company
-36.7%
Current Industry
2.9%
PIRS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PIRS Return on Capital Employed

Current Company
-91.72%
Current Industry
19.5%
PIRS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PIRS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PIRS$42.81M-$22.76M-$24.54M+8.03%N/A
CDIO$17.07k-$1.53M-$8.38M+335.20%N/A
NNVC$0.00-$8.55M-$9.36MN/AN/A
XTLB$0.00-$1.78M-$1.78MN/AN/A
EDSA$0.00-$7.52M-$7.72M-100.00%N/A
View Top Biotech Stocks

PIRS earnings dates

Next earnings date
Jun 20, 2024

Pieris Pharmaceuticals Earnings & Revenue FAQ

What were PIRS's earnings last quarter?

On Invalid Date, Pieris Pharmaceuticals (NASDAQ: PIRS) reported Q4 2023 earnings per share (EPS) of -$3.20, up 63.64% year over year. Total Pieris Pharmaceuticals earnings for the quarter were -$4.58 million. In the same quarter last year, Pieris Pharmaceuticals's earnings per share (EPS) was -$8.80.

If you're new to stock investing, here's how to buy Pieris Pharmaceuticals stock.

What was PIRS's earnings growth in the past year?

As of Q2 2024, Pieris Pharmaceuticals's earnings has grown year over year. Pieris Pharmaceuticals's earnings in the past year totalled -$24.54 million.

What is PIRS's earnings date?

Pieris Pharmaceuticals's earnings date is Invalid Date. Add PIRS to your watchlist to be reminded of PIRS's next earnings announcement.

What was PIRS's revenue last quarter?

On Invalid Date, Pieris Pharmaceuticals (NASDAQ: PIRS) reported Q4 2023 revenue of $1.30 million up 77.78% year over year. In the same quarter last year, Pieris Pharmaceuticals's revenue was $5.85 million.

What was PIRS's revenue growth in the past year?

As of Q2 2024, Pieris Pharmaceuticals's revenue has grown 65.28% year over year. This is 77 percentage points lower than the US Biotechnology industry revenue growth rate of 142.27%. Pieris Pharmaceuticals's revenue in the past year totalled $42.81 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.